Table 2.
Concentration of markers in early (S1) and late (S2) stage T.b. rhodesiense patients
| Marker | [S1], median | [S2], median | [S2]/[S1] | p value* | Spearman rho† |
|---|---|---|---|---|---|
|
IgM [μg/mL] |
0.96 |
65.4 |
68.1 |
<0.0001 |
0.491 |
|
MMP-9 [pg/mL] |
108.6 |
1309.9 |
12.1 |
<0.0001 |
0.554 |
|
CXCL13 [pg/mL] |
8.2 |
1531.2 |
186.7 |
<0.0001 |
0.529 |
|
VCAM-1 [ng/mL] |
22.6 |
67.3 |
3.0 |
<0.0001 |
0.372 |
|
B2MG [ng/mL] |
964 |
3447 |
3.6 |
<0.0001 |
0.426 |
|
ICAM-1 [ng/mL] |
1.99 |
9.6 |
4.8 |
<0.0001 |
0.457 |
|
Neopterin [nmol/L] |
41.2 |
112.9 |
2.7 |
0.001 |
0.360 |
| CXCL10 [ng/mL] | 8.9 | 41.9 | 4.7 | 0.005 | 0.508 |
* Mann–Whitney U test.
† Correlation between the number of CSF WBC and CSF levels for each marker. Correlation was significant at 0.01 level.